prednisone oral solution / Boehringer Ingelheim - LARVOL DELTA

CAR T-cell Therapy Is the Leading Edge of Care for Post-transplant Lymphoproliferative Disorder (Fred Hutchinson Cancer Research Center) - "'Until recently, the use of CAR T-cell therapy for PTLD had been largely unknown,' says Christopher Blosser, MD...'Aggregated data from our case and the 16 previously published reports show this treatment is safe and effective. CAR T-cell therapy does not appear to cause organ rejection and has limited side effects when compared to other chemotherapies and immunotherapies'....Blosser recommends patients have at least one visit in the clinic. 'More often than not, at least one appointment can help facilitate optimal steps in a patient's care,' he says. 'And the earlier we meet that patient, the more likely we can help improve their outcomes.'"

Media quote

[VIRTUAL] CARE PATTERNS OF PATIENTS WITH CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE (ILD) WITH A PROGRESSIVE PHENOTYPE (AMCP 2021) - "The most common medication filled during follow up was prednisone, with 47.2% of patients filling at least one prescription for it. Non-IPF patients with chronic fibrosing ILD with a progressive fibrosing phenotype had prevalent respiratory comorbidities. These patients frequently used OCS, DMARDs, and immunomodulator medications."

Clinical • Chronic Obstructive Pulmonary Disease • Fibrosis • Idiopathic Pulmonary Fibrosis • Immune Modulation • Immunology • Inflammation • Interstitial Lung Disease • Obstructive Sleep Apnea • Pneumonia • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Sleep Disorder

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis (clinicaltrials.gov) - P2; N=33; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Recruiting ➔ Active, not recruiting; N=68 ➔ 33

Clinical • Enrollment change • Enrollment closed • Breast Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Pneumonia • Solid Tumor • Thoracic Cancer

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis (clinicaltrials.gov) - P2; N=68; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Jul 2020 ➔ Jul 2021; Trial primary completion date: Jul 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis (clinicaltrials.gov) - P2; N=68; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Jul 2019 ➔ Jul 2020; Trial primary completion date: Jul 2019 ➔ Jul 2020

Clinical • Trial completion date • Trial primary completion date